313 related articles for article (PubMed ID: 32183301)
1. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Jette NR; Kumar M; Radhamani S; Arthur G; Goutam S; Yip S; Kolinsky M; Williams GJ; Bose P; Lees-Miller SP
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183301
[TBL] [Abstract][Full Text] [Related]
2. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
3. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
4. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.
Wang C; Jette N; Moussienko D; Bebb DG; Lees-Miller SP
Transl Oncol; 2017 Apr; 10(2):190-196. PubMed ID: 28182994
[TBL] [Abstract][Full Text] [Related]
5. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
6. Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Węsierska-Gądek J; Heinzl S
J Cancer Prev; 2014 Jun; 19(2):125-36. PubMed ID: 25337581
[TBL] [Abstract][Full Text] [Related]
7. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
Southgate HED; Chen L; Tweddle DA; Curtin NJ
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354033
[No Abstract] [Full Text] [Related]
8. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
9.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
10. Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G
Mak JPY; Ma HT; Poon RYC
Mol Cancer Ther; 2020 Jan; 19(1):123-134. PubMed ID: 31597711
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
12. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
13. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
[TBL] [Abstract][Full Text] [Related]
14. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
Ariumi Y; Turelli P; Masutani M; Trono D
J Virol; 2005 Mar; 79(5):2973-8. PubMed ID: 15709017
[TBL] [Abstract][Full Text] [Related]
15. Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
Setton JS; Powell SN
Cancer Res; 2020 Jun; 80(11):2085-2086. PubMed ID: 32487588
[TBL] [Abstract][Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
18. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
20. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
Thomas A; Fontaine SD; Diolaiti ME; Desai P; Kumar R; Takahashi N; Sciuto L; Nichols S; Ashworth A; Feng FY; Ashley GW; Nguyen M; Pommier Y; Santi DV
Mol Cancer Ther; 2022 Nov; 21(11):1722-1728. PubMed ID: 35999657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
